Spirax Group plc (SPX) Earnings Call Transcript & Summary
August 11, 2022
Earnings Call Speaker Segments
Operator
operatorGood morning, and thank you for standing by. Welcome to the Spirax-Sarco Engineering PLC 2022 Half Year Results Webcast and Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Nicholas Anderson, Group Chief Executive. Please go ahead, sir.
Nicholas Anderson
executiveGood morning, everyone, and welcome to our 2022 Half Year Results Announcement Call. I'm Nicholas Anderson, Group Chief Executive, and I'm joined here by our CFO, Nimesh Patel. Regarding today's presentation, I will start by sharing the highlights of the first half, and then Nimesh will take you through our financial performance. Later, I will return to cover the operations and outlook for the full year 2022. To finalize, we'll be happy to take questions from the analysts on the call. Moving to Slide 3. I'd like to start by acknowledging and thanking all my colleagues around the Group for their outstanding efforts to meet exceptional customer demands in what has been a challenging first half year. Across the Group, we have seen continued strong demand growth, despite challenging environment and softening IP. All 3 businesses entered 2022 with record order books and all 3 have expanded their order books during the first half. We saw particularly strong demand for larger project orders as customers accelerate capital investments. In addition to delivering increased volumes, as we ramped up our shipments from our manufacturing facilities, we have continued to actively implement price increases to offset inflation and protect margins, in-line with our well-established practices. In Steam Specialties and ETS, we saw sales growth well ahead of IP and demand growth well ahead above sales, with both businesses continuing to expand their order books beyond their record opening positions. In Watson-Marlow, sales were significantly up. Demand from customers in the biopharma sector has normalized in line with our expectations and reflecting lower COVID-19 related demand, while growth in the Process Industries was significantly above IP. Watson-Marlow's order book at the half year remains above their opening position at the beginning of this year. As expected, CapEx has risen to record levels during the first half, driven by increased investments in our manufacturing capacity to support growth, particularly in Watson-Marlow. And Nimesh will provide further performance details in the financial section. So now moving on to Slide 4. The global supply chain challenges that kicked off in the latter part of 2021 were still present in the first half of 2022, impacting the availability of key manufacturing components such as Nylon, printed circuit boards and semiconductors. We continue to engage with our supply chain partners to deploy our mitigation strategies, successfully maintaining deliveries that met customers' requirements. In March, we announced our decision to suspend all Group trading with or within Russia. And on the 6th of July, we concluded the disposal of our Spirax-Sarco Watson-Marlow operations to the local management for a nominal consideration. During the first half of 2022, we continued our revenue investments to support growth across all 3 of our businesses, including accelerating our digital initiatives. We also continued investments to further expand manufacturing capacity through factory modernization and debottlenecking initiatives. These include new equipment, revised processes, additional people and new manufacturing plants in Watson-Marlow. We have continued to make further progress on our ESG agenda, and I will provide more detail on this in a moment. Our business development teams in ETS and Steam Specialties continued collaborating to address the substantial sales opportunities arising from decarbonization, and which I will expand upon when we get to the ETS section. Also in ETS, we made good progress to address the financial underperformance of the Chromalox facility at Soissons in France, and this process should be completed by year-end. Lastly, on the 25th of July, we signed a binding agreement to acquire Vulcanic for a consideration of EUR 262 million. So now on to Slide 5. The acquisition of Vulcanic represents a significant milestone to strengthen our ETS business. Vulcanic is a European industrial electric heating group and is the largest supplier in Europe of bespoke industrial electric heating solutions. It operates a direct sales model, has 10 manufacturing facilities worldwide and employs over 700 people, of whom almost 90% are based in the EMEA region. Vulcanic has a clear strategic fit with our ETS business, and it expands our platform to deploy the Group's business model, driving further improvements in sales growth and margin over time. Vulcanic has a strong complementarity with Chromalox through its existing customers', products, and operational footprints, including a strong focus on decarbonization. It also balances our geographic footprint by strengthening ETS's presence in the EMEA region where we expect to see the strongest demand for decarbonization solutions in the near term. Together with the actions we're taking at Chromalox in Soissons, Vulcanic establishes a larger profitable footprint in EMEA. Now Vulcanic's pro forma performance in 2021, following its acquisition of EML in the U.S.A. in December of 2021, includes revenues of EUR 89.4 million, adjusted EBITDA of EUR 17.6 million, and adjusted operating profit of EUR 16 million. This transaction is expected to close late in this third quarter. Turning now to Slide 6 and the ESG. As I mentioned, we have continued progressing our Group's ESG agenda. Our Ten Inclusion Commitments, which form part of our inclusion plan called Everyone Is Included, are being cascaded globally through a series of inclusion master classes, webinars and workshops to embed this commitment into local policy and practice across the Group. We also formally signed the UN Women's Empowerment Principles in UN LGBTI standards and joined the Women's Engineering Society to help advance our gender equity journey. I was particularly proud that our colleagues raised GBP 92,000 towards our total donation of GBP 284,000 to the Ukraine Red Cross Appeal. And we were very pleased to make the first awards of our newly established Group Education Fund, which totaled more than GBP 230,000 across numerous projects globally. We have also made further investments in health and safety, including a new Global Health and Safety Management System and Behavioral Based Safety training programs on a global scale. From an environmental perspective, we have now secured green contracts for close to 40% of our Group's electricity supply and launched over 50 biodiversity projects globally. We achieved a significant reduction in absolute Scope 1 and Scope 2 market-based emissions as measured against the first half of 2021 and initiated implementation of Project Clear Sky to fully decarbonize our Steam Specialties U.K. manufacturing facility in Cheltenham. Every manufacturing facility has also developed their initial net zero road maps, which are being refined and incorporated into their operating plans. These are just some of the many internal ESG initiatives of the first half. In addition to our continued work to support our customers to improve their sustainability performance, which include bringing to market our suite of TargetZero solutions for decarbonizing steam generation. And I'll come back to that in a moment. And with that, I'll now pass you on to Nimesh.
Nimesh Patel
executiveThanks Nick, and good morning everyone. Nick and I are pleased to be presenting another strong set of results, delivered against the backdrop of macroeconomic uncertainty and challenges in the industrial operating environment, some of which we expect to persist in the second half and beyond. I'll explain the drivers of our financial performance, which underpin our improved outlook for the full year. Moving to Slide 8. As always, the numbers we will be discussing are the adjusted results. Adjusting items include over GBP 15 million of costs relating to the restructuring of Soissons, our ETS manufacturing facility in France, and almost another GBP 7 million of costs related to our acquisitions of [ Cotopaxi ] and Vulcanic in addition to our exit from Russia. Further details are included in the appendix. Sales was 17% higher, reflecting an organic increase of 15%, and operating profit was 10% higher or 9% on an organic basis. The difference between our reported and organic growth rates reflects the positive effect of currency movements on sales and profit and the adverse impact of our exit from Russia, partially offset by our acquisition of Cotopaxi. These impacts are reflected in our reported numbers and excluded from our organic growth rates. Our operating profit margin decreased by 150 basis points on both a reported and organic basis to 23.8%. In line with previous guidance, this margin reduction was driven by the full year impact of revenue investments made during 2021 and continued investments in 2022. Net finance expense remained the same as the first half of 2021. We estimate an increase of GBP 2 million in the second half related to the acquisition of Vulcanic. Our effective tax rate in the first half, which is based on the expected full year tax rate was 26%, again, in line with guidance. EPS at 175.1p was 11% higher, broadly in line with the increase in operating profit. In respect of the first half, we're proposing an interim dividend of 42.5p reflecting our strong first half performance and our confidence in the full year outlook. This is an increase of 10%, following an increase of 15% in the total dividend for 2021. Our dividend cover will remain at the top end of our stated range of 2x to 2.5x. Moving to the sales bridge on Slide 9. Currency movements had a positive impact of over GBP 11 million on sales or 2%, driven by a weakening of sterling, particularly against the U.S. dollar. If July month end rates were maintained for the rest of the year, we would expect to see a slightly higher positive effect of around 3% for the full year. Acquisitions and disposals includes the net contribution from Cotopaxi acquired in January and the impacts of our decision to suspend trading with and within Russia from March onwards. The effect on sales was less than 1% in the first half and is expected to be similar for the full year. The Group's organic growth in sales was 15%. All 3 businesses delivered strong organic sales growth, driven by higher volumes, as well as price increases. We increased output from our manufacturing facilities supported by prior and current investments, although our order books still expanded from their already record levels as demand continued to exceed sales. Organic growth in Steam Specialty sales was 10% with demand growing significantly above IP. This was despite growth in Asia Pacific being impacted by a COVID-19 related lockdown in China during the second quarter. ETS organic sales growth was 13%, driven primarily by Chromalox and despite lower sales in EMEA due to a significant reduction in output from our plant in Soissons, France. In Thermocoax, organic growth was lower than the average for ETS, reflecting the longer lead times on shipments of new orders to the nuclear and semiconductor markets. Watson-Marlow once again performed very strongly with organic growth of 26%. Process Industries demand growth was significantly above IP. And while biopharm demand has normalized on lower COVID-19 vaccine-related demand, overall demand still exceeded sales. We expect Group revenues in 2022 to reflect the typical split of around 48% and 52% between the first half and second half of the year prior to reflecting the impact of Vulcanic. The next bridge on Slide 10 highlights the movement in adjusted operating profit for the half year. Currency movements increased profit by GBP 3.5 million or 2%, as a result of both translational and transactional impacts. If July's month end rates were maintained for the rest of the year, we would expect to see a slightly higher positive effect of around 3.5% for the full year. The net effect of acquisitions and disposals reduced profit by GBP 1.8 million or just over 1% and is expected to be similar for the full year. The total organic increase in Group operating profit was 9%. Steam Specialties profit grew 2% organically. As anticipated, this was below our organic growth in sales due to the full year impact of our 2021 revenue investments and our continuing investments in 2022, which offset the benefit of operational gearing from higher sales. ETS profit increased 9% organically with profit growth higher in Chromalox than in Thermocoax, reflecting the strong growth in Chromalox sales. Watson-Marlow's organic profit growth of 21% reflected the very strong sales growth in the first half, and like Steam Specialties, was below organic growth in sales due to the full year impact of our 2021 revenue investments and the ramp-up of our new BioPure manufacturing facility in the U.K. The increase in central expenses reflects increased investment to deliver on our strategic initiatives such as sustainability and strengthening our governance in addition to higher charitable donations. Turning to Slide 11. Our adjusted operating profit margin decreased to 23.8%, in line with our guidance and which is above pre-pandemic levels and the second highest first half margin in our Group's history after 2021's record 25.3%. This 150 basis point reduction in margin reflects the full year impact of our 2021 revenue investments, which support the future growth of our business. When presenting our 2021 results, we estimated the full year impact of these investments would have reduced the Group's 2021 margin by less than 200 basis points. During the first half of 2022, we have continued with our revenue investments and the ramp-up of our new manufacturing sites, including Watson-Marlow's new BioPure facility at Dunsbury Park in the U.K. and Thermocoax's new facility in Normandy, France. And in the second half, Watson-Marlow will also ramp up its new U.S. facility at Devens. Across the Group, we have also continued to successfully deploy our active approach to price management during the first half of 2022 to offset inflationary pressures and protect our adjusted operating profit margin. We anticipate the full year adjusted operating profit margin in 2022 will be similar to the first half as we continue to invest for growth, which will offset the benefits of operational gearing from higher sales in the second half. Nick will talk about the margin performance in each business shortly. Turning now to cash flow on Slide 12. Operating profit to operating cash conversion was 44% due to investment in working capital and increased capital expenditure. Our ratio of working capital to sales increased to 24%, up over 200 basis points from the end of 2021. This reflects a planned rebuilding of stock to meet increasing demand and mitigate supply chain-related shortages of raw materials, as well as an increase in receivables. Going forward, we anticipate a reduction in this ratio of working capital to sales to a similar level as reported in 2021 as shipments increased in the second half of the year. The most significant driver of the increase in capital investment relates to our previously announced expansions of Watson-Marlow's manufacturing capacity, particularly in the U.S. The construction of this U.S. facility is the largest project in our Group's history with an expected cost of $106 million, the bulk of which will be incurred in 2022. We anticipate capital expenditure for the full year will be approximately 7% of sales. And as a result, we anticipate that cash conversion for the full year will be higher than in the first half, but lower than our historical levels of around 90%. We ended the first half with net debt of GBP 203 million, up from GBP 131 million at the end of last year, and net debt equated to 0.5x EBITDA. Net debt will increase in the second half following the completion of our acquisition of Vulcanic. Thank you. And I will now hand you back to Nick to run through our view of industrial production and our business performance.
Nicholas Anderson
executiveThank you, Nimesh. On Slide 14, we have once again shared the sequential evolution of -- by quarter, of Global Industrial Production output. As you all know, Global Industrial Production growth or IP for short, is the best predictor of our markets. The blue line represents Oxford Economics IP forecast for 2022, 1 year ago in July 2021. The green line represents their forecast on the 23rd of February, the day before Russia invaded Ukraine, which we shared with you at our full year results announcement in March. The red line is Oxford Economics' latest forecast published on the 15th of July. Now the first point to note is the stronger-than-expected global IP output in the first quarter of this year, followed by the 1.5% global output contraction that followed in the second quarter of 2022. This contraction was mostly a result of the heightened uncertainties caused by the war in Ukraine, COVID-19 lockdowns in China, rising Google inflation and corresponding monetary policy actions, all of which compounded the continued global supply chain disruptions. Consequently, over the past 6 months, global IP growth forecast for 2022 was systematically downgraded from 4.4% to 3.5%. Given the still uncertain macroeconomic environment, it is plausible that this forecast could still suffer further downward revisions. In fact, last night, after this presentation was finalized, we received a new update from Oxford Economics, lowering the 2022 global IP forecast to 3.3% for this year. Nevertheless, our robust business model and disciplined execution of our strategies have underpinned the resilience of our performance throughout economic cycles. So we remain confident in our ability to successfully navigate the continued uncertainties ahead. Now on Slide 15, we start the half year review of our operations with the Steam Specialties business. Steam Specialty sales were up 11% to GBP 400.6 million or 10% up organically. Adjusted operating profit was up 3% to GBP 92.1 million or 2% up on an organic basis. The adjusted operating profit margin of 23.0% was down 180 basis points on both a reported and organic basis. As we continued our revenue investments in support of growth, including in our digital strategy. Demand for Steam Specialties products and solutions grew significantly above global IP in the first half of 2022 and well above sales as the business expanded its order book further from its record opening position. Demand remained strong across all regions and most market sectors. Contributions from Cotopaxi acquired in January 2022 to accelerate our digital enablement journey were more than offset by the disposal of our Russian operations. We anticipate sales growth for the full year 2022 will continue to significantly outperform current full year forecast of IP. As anticipated, the first half adjusted operating profit margin was 180 basis points lower due to the full year impact of our 2021 and 2022 revenue investments, which offset the benefits of our operational gearing from higher sales, as Nimesh explained just recently. We expect on a similar impact on the full year 2022 adjusted operating profit margin compared to the full year 2021. Moving to Slide 16. ETS sales of GBP 104.7 million were up 13% organically or 18% on a reported basis, benefiting from a 5% currency tailwind as sterling depreciated against the U.S. dollar. The adjusted operating profit of GBP 12.8 million was up 9% organically and resulted in an adjusted operating profit margin of 12.2%, 60 basis points down organically due mostly to the revenue investments for growth. Within ETS, Chromalox increased its adjusted operating profit margin organically, driven by continued strong performance in the Americas, where margins are above 20%. The profitability of the Soissons facility in France has been addressed through a consultation process. And adjusting for losses incurred in Soissons during the first half of 2022, the ETS adjusted operating profit margin would have been higher than in the first half of last year. And as I mentioned already, following the completion of successful field trials, the first decarbonization solutions developed through the Thermal Solutions Synergy project, in collaboration between Steam Specialties and ETS are now available. Collectively known as TargetZero, these new and innovative solutions are designed to help our customers decarbonize their critical industrial processes, including the raising of steam. For the full year 2022, we anticipate ETS sales growth will be significantly ahead of global IP and similar to the first half, growing above Steam Specialties. As a result of the operational gearing from increased sales, we anticipate adjusted operating profit growth ahead of sales growth in 2022, with an increase in the adjusted operating profit margin for the full year. The Vulcanic transaction is expected to close in the third quarter of 2022 following the receipt of regulatory approvals. Vulcanic's organic sales growth in 2021 and during the first half of 2022 was similar to ETS and we expect the full year 2022 sales growth for Vulcanic to be similar to ETS's. Now on Slide 17, Watson-Marlow sales of GBP 244.8 million were up 26% organically, while the adjusted operating profit for the first half was up 21% organically to GBP 87 million, driven by strong sales growth. The adjusted operating profit margin of 35.5% was down 170 basis points organically, reflecting our continued revenue investments and the recruitment of additional colleagues for our new manufacturing facilities. Supported by increasing demand for gene and cell therapy treatments, underlying demand for Watson-Marlow's products remained strong. Demand from customers in the pharmaceutical and biotechnology sector normalized in line with our expectations and reflecting lower COVID-19-related demand. While in the process industries, demand growth was significantly above IP. Watson-Marlow's overall order book at the half year remains above the 2021 year-end position. Sales to the pharmaceutical and biotechnology sectors grew by close to 30%, reflecting increased deliveries from the significantly large order book, while sales to the process industries grew significantly above IP. Watson-Marlow continued making significant progress in expanding its manufacturing capacity during the first half of 2022. Our newly installed capacity at BioPure in Portsmouth, Watson-Marlow Pumps and Tubes in Falmouth and Aflex Hoses in Huddersfield, enabled almost 40% increased production output across those 4 key plants compared to the same period of 2021. In 2022, we continue to anticipate around 20% organic sales growth to the pharmaceutical and biotechnology sector. After the process industry sectors, we anticipate similar organic sales growth to that of the first half, remaining significantly ahead of Global IP. While we expect strong sales growth in the second half of 2022, the organic sales growth rate will be lower than that achieved in the first half, reflecting the strong second half comparator of 2021. We anticipate that for the full year 2022 the adjusted organic operating profit margin will be below 2021, reflecting the full year impact of our 2021 and 2022 revenue investments, as well as the ramp-up of our new manufacturing capacity. However, the margin will remain comfortably above 2020. Moving on to Slide 18. We have again added 3 new customer case studies that help illustrate how our 3 businesses improve the performance of our customers and help them achieve their sustainability targets by reducing energy expenditure and waste, while contributing to a more efficient, safer and sustainable world. These case studies are in Appendix 1 to 3 of this presentation, and I'd encourage you to read more about them at a later moment. Now that concludes today's presentations. So we will now be pleased to take questions from the analysts on the call. And with that, I'll hand back to Nadia.
Operator
operator[Operator Instructions] And the first question comes from the line of George Featherstone from Bank of America.
George Featherstone
analystMy first one would be on the order book. I wonder if you could help us understand a bit more about the increase year-on-year here. What contribution do you think there's been from price and how much from volume in that increase? And also, how much visibility do you have now compared to typical levels?
Nicholas Anderson
executiveGeorge, thanks for your question. Look, the -- yes, the order book is up, and it's up by those 2 reasons, the price and the volume. The visibility is the same as we've always had, right? So you know that we have typically long -- short lead times, and therefore we have limited visibility, although high predictability, and we always remind people of that. So that visibility remains the same. We've historically operated on 7 or 8 weeks, 7 to 8 weeks of order book and those are usually the longer cycle orders that sit for a bit longer in the order book. And we do have across the board, the Group, as you know, yes, close to 40% of our business that actually is booked and shipped within the same month. And therefore, that limits the visibility. Now, if we've said clearly that the order intake of this year and the sales of this year have been impacted favorably by both volume growth and sales growth, you would expect that same mix to be reflected in the order book at the moment because of the short lead times that we've mentioned.
George Featherstone
analystOkay. Very clear. Maybe then turning to the payback period that you typically offer for customers, which is already -- or historically has been very short anyway. But I wondered how much of that has changed maybe in the prevailing energy cost environment for Steam and ETS? And also how much of the demand growth across those 2 businesses would you attribute to growing need to reduce energy costs for your customers as we look forward?
Nicholas Anderson
executiveSo the -- look, the -- are you particularly interested in, if the payback of decarbonization solutions is longer than the payback of the other projects that we've usually been doing. Is that what you're trying to understand?
George Featherstone
analystWell, I'm just trying to understand, if the payback period has changed because when customers are looking at maybe upgrading those systems, it might be against now higher energy costs that they can offset through some of the improvements that you can give. So I just wondered if there's been a change versus history in terms of the payback period that you'd normally be able to offer?
Nicholas Anderson
executiveYes. So okay. First, as a reminder, Energy savings is just one of the many ways in which we help our customers improve their performance, right? So it's a more visible one, easier to visualize, but it's not the only reason why customers -- not the only way in which we help our customers improve their performance and reduce their costs. So inevitably, the part that is related to energy savings will benefit from a slightly shorter payback if the energy costs go up or will lengthen a little bit when the energy costs go down. But it doesn't materially change the overall situation that we have been seeing with our customers, because it's not -- energy cost is not the only reason why customers are reflecting that. When it comes to decarbonization solutions, and that's why I was inquiring if that's where you were, right. It does extend a little bit. So when the customer is looking to, for example, decarbonize one of his operations, the driver there is reduction of carbon footprint, not the energy costs. And actually, the cost of electricity are higher than gas, and therefore, that does change a bit of the equation. But really, the driver there tends to be a reduction of carbon footprint as opposed to energy costs.
George Featherstone
analystOkay. And final one for me would be on the large project demand that you've seen an increase in. Just wondered if you could maybe run us through particular customer segments that you've seen this in? And is it more in the Asia Pacific region where you've seen this, because that has historically been, I think, the area where large projects should be mostly found?
Nicholas Anderson
executiveOkay. Yes. Thanks, George. Good question. Yes, look, yes, APAC is where we see a lot of -- or a higher proportion, if you want, of CapEx-driven sales, customer CapEx in sales, new builds, design of new facilities or expansion -- brownfield expansion of new facilities. And so yes, that is reflected this year as it has been historically. The nature of that is mostly across all sectors. I wouldn't call out any individual sector as having seen more CapEx investments by customers than in other sectors. And really, what this is, is the expected return to normality after the slowdown during 2020 because of COVID. So as you remember, 2019, global IP was already coming down. In fact, it was close to 1% in that year. So many companies were already reviewing their capacity expansions, because when we talk about CapEx, customer CapEx projects, it's essentially customers expanding their capacity. -- either through greenfield or brownfield expansion. So when the demand of the customers' products, the expansion because when we talk about CapEx, customer CapEx projects is it's essentially customers expanding their capacity, either through greenfield or brownfield expansion. So when the demand of the customers products start softening as it was in 2019, the need to expand that capacity eases a bit, and we're already seeing that slowdown in 2019, then come 2020 with the pandemic, everything stopped because it wasn't clear. And then once the situation started becoming clearer in 2021, customers started pulling those projects out and reviewing those projects and you started seeing those orders coming in at the end of last year and the beginning of this year. So it is really a return in that sense and somewhat of a catch-up from the slowdown that goes back to 2019, really.
Operator
operatorNow we are going to take our next question. And the question comes from the line of Aurelio Calderon Tejedor from Morgan Stanley.
Aurelio Calderon Tejedor
analystNicholas and Nimesh, it's Aurelio Calderon from Morgan Stanley. The first one is around the process part of Watson-Marlow and I think the implied guidance or the implied performance in the first half is quite encouraging, close to 20% growth. So what's driving that growth? Is it again market share gains? Is it that your pumps are displacing other type of pumps? Or what is the driver behind that strong growth and kind of the forward-looking demand comment, which also looks quite encouraging.
Nicholas Anderson
executiveOkay. Aurelio, thanks for your question. Look, the process industries, as you will recall, is a collection of multiple sectors. The main ones are food and beverage, water and wastewater, and water treatment processes, a little bit of precious metals, mining, et cetera. So there is a variety of sectors. In all of those sectors, as is not typically across all of the businesses of our Group, we do tend to gain market share through the sale of solutions for customers, which is what we call the uncovering the need -- unrealized needs of the customers. So it is the same, we've shared in the past, where our sales engineers walk to plants of the customers, identify ways in which they can improve the customers' performance through the use of our products. And then we'll look for those opportunities to either share products or services that improve the customers' performance. So when we do that, inevitably, there is some market share gain because sometimes you might be displacing, in the case of Watson-Marlow, other types of pumps, for example, where the adoption of our pump solutions improves their performance, but to the detriment of a different type of pump that they might have been wearing -- using previously. And therefore, that is a form of market share gain inevitably. But it's no different to the operating model that we've shared with you in the past. And for that reason, we continue to see that trend positively progressing. And it is that those characteristics that I've just described that explain why the Process Industries and Watson-Marlow grow at an even faster outpaced than IP compared to other parts, because it's that stronger displacement of other types of pumping technologies by the Watson-Marlow products.
Aurelio Calderon Tejedor
analystOkay. That's helpful. And the second question is around pricing. And I know you haven't really called out the price increases in the first half. But if we think about these prices kind of sticking, do you see any differences by division, by business by geography? Or maybe you can kind of hold on to those price increases as kind of inflation moderates a little bit into 2023?
Nicholas Anderson
executiveOkay. Thank you, Aurelio. Good question. Look, let me start by reminding yourself and all the other listeners on the call that we have very well-established processes across all 3 of our businesses, deeply embedded now, what we call the price management processes, right? And therefore, for years now, the organization has been trained and has successfully managed to pass on inflationary increases to protect our margins. And therefore, what happens when inflation ramps up is that we have to ramp up our corresponding price increases to customers. Inevitably, in a year where there's an acceleration as we've seen at the beginning of this year, that would lead -- and it did lead, in fact, for example, to further price increases in the first half than we had originally planned for. When we did our plans for 2022 at the back end of last year, we were anticipating a level of inflation, which clearly at the end of the first quarter was noticeably higher than what we had planned for. So we went back and we did a little reinforcement of the price increases that we put through as inflation was coming through and larger. And to be honest, customers we have like taking a price increase, but they understand it. They understand it because we're very transparent, and we demonstrate to the customers. And of course, the customers are experiencing the same thing in their own businesses. So whilst it's never easy, and it shouldn't be taken for granted, I think we have well embedded processes, and we've seen that come through. And actually, in the second quarter, we were worried if that reinforcement of price increases would be strongly push back or not. And the pushbacks were in line with what we expected and has, therefore, come to -- and that gives us the confidence that our margins are protected. And in the second half, we think now that the worst of that is behind us. And so at this point, we're not anticipating the need for further price increases through the balance of this year. And that does not change by division or by geography or by market sector. Some channels are easier than others, but the principles are the same across all parts of the Group.
Aurelio Calderon Tejedor
analystThat's helpful. And maybe if I can just squeeze one last question. On the ETS benefit from electrification and decarbonization, are we seeing that in the numbers already? Because obviously, your growth in ETS was ahead of Steam in the first half after kind of years of underperformance in Steam and your forward-looking comments is also a bit more positive on ETS. And I also remember from the ETS Investor Day, you were talking more positively about this business going forward than for Steam probably. So is that benefit [ holding] in the numbers right now? Or are we still kind of in that wait-and-see mode to see when this decarbonization and electrification benefits kick in?
Nicholas Anderson
executiveYes. We are already beginning to see some benefits in the order book, in fact, since the end of last year already. So -- but as we said at -- for those of you that were able to follow the ETS Capital Markets Day at the end of June, this is a new and additional incremental trend to all the other trends that we see in our business. The global move to decarbonize Industrial Processes is a process that has started, is a trend that is on its way. And -- but it's really just getting started, okay? Also it's very difficult to predict the rate at which this trend will further improve our ability to outperform IP growth going forward. But we know what's happening, and it's already beginning to contribute, obviously, on a smaller scale because it's the beginning of the process. But yes, we've really received multiple orders since the end of last year or even before. And so we see this trend is already a reality, but it's the beginning of the curve. So it's not the most significant driver yet, but it will build over the years to come as a more substantial contributor to our growth.
Operator
operatorNow we are going to take our next question. And the next question comes from the line of Jonathan Hurn from Barclays.
Jonathan Hurn
analystI just have 3 questions, please, if I may. Just in terms of the first one, can you just talk a little bit more about Vulcanic, please? Potentially about what synergies you can get from that deal by putting it together with Chromalox? Also essentially what investment is needed or what investment you think might be needed in Vulcanic going forward? And also, how do we think about the margins for Vulcanic? Is your aspiration to get that margin of that business pretty much up to the Group average? That was the first question.
Nicholas Anderson
executiveThanks for asking about Vulcanic, because we are very excited. We think this is a really strong complementary opportunity for us. We had been pursuing it. And we have been tracking it for some years, because it was privately equity owned. And therefore, we knew that sooner or later it was going to come to the market. In fact, it was expected to come to market earlier, but got delayed by COVID and so many other things. So we see and why we're very excited, because we see this as a very strong complementarity with Chromalox. Basically, when you look at Vulcanic, it's pretty much the Chromalox of Europe. And I'm reminding everybody that the Chromalox is strongly present in the Americas, in the U.S.A., in particular, but very light still in Europe and EMEA and Vulcanic is the other way around. So there's that first geographic complementarity. But the products, the technologies, the services are very aligned. However, this is another great point, not necessarily overlapping in market sectors. So when we do our traditional sectorized view and approach, you'll see that, for example, Vulcanic has good, a significant part of their sales going into food and beverage applications and supplying, for example, to food and beverage OEMs. OEMs that are making, for example, ovens for bakeries or for food processing. That's a sector where Chromalox hasn't been focused on, and Vulcanic has got a good presence. So we see not only geographical, but also segment, sector, market sector complementarities in that sense. There's also another interesting synergy for us is that they've got a well-established efficient and profitable manufacturing footprint across Europe, which, as you know, Chromalox didn't have. We only had basically one plant in Soissons, which, as you all know was historically loss-making and underperforming and really -- well, we're now in the process of closing. So that left us really without a good industrial footprint to manufacture the Chromalox products in Europe, which we will continue to do, because this will be market sector-driven dual-brand strategy in ETS in exactly the same way and following the same footprint of the successful dual brand strategy that we've established over the last 5 years between Spirax and Gestra in the Steam Specialties business. And that's exactly the footprint that we're using. So when you think of the complementarity and the synergies, the revenue synergies between Vulcanic and Chromalox, you just need to look at what we've done between Spirax and Gestra and model that into Vulcanic and Chromalox and ETS. So that's -- but additionally, we do have these manufacturing savings or cost revenues because now we can manufacture the Chromalox products going forward in what is today Vulcanic manufacturing plants locally without having to rely on making those in the U.S. and shipping across to EMEA. And that, therefore, gives us additional synergies in that sense. So we are very excited and looking forward to having the Vulcanic team join the family in, hopefully, by the end of next month. So in terms of investments required, look, there's always investments required, but I have to say the team at Vulcanic has done a good job. I've personally visited a few of the top factories and could see firsthand that they're not as underinvested as one sometimes fears when the business has been under private equity ownership for a longer period of time as they were. So in that sense, we saw some areas which will require investment inevitably, and we factored that into our plans, in order to bring them up to the standards of performance that we expect across our Group. But it's not more than we were expecting. So that's in line with our expectations. And in terms of margin progression, the first thing to remember is that Vulcanic is already mid-teens profitability business. We haven't got, I'm glad to say, a loss-making underperforming plant of part of Vulcanic as we had when we acquired Chromalox and we knew that when we acquired Chromalox. We knew that Soissons was loss making. It was going to be a problem, and you followed over the last 5 years, all our efforts to try to fix it without having to close it. We haven't got that situation in Vulcanic. So, whilst the investments that we'll be making to Spiraxize Vulcanic once they join the family, will inevitably dampen their margins a little bit in the first couple of years, and that's part of our model, as you all know. The gap to get to or above 20% margins is smaller and therefore -- and there is the dispersion that we had in Chromalox in terms of good performing and bad performing parts of the Group. So we can see the margin progressing up to or beyond 20% over the coming years, in line with our Group strategies for all across the Group.
Jonathan Hurn
analystThat's super helpful, very clear. Second, can I just again sort of maybe focus on sort of revenue investment and obviously what you're seeing in the business currently. Obviously, there's a lot of that happening that's going to come through in the second half as well to depress margins. But as we look to FY '23, do we still see that scenario as a lot of that sort of revenue, one-off revenue investment pretty much finished. So possibly there's a bounce back in operating efficiency in '23?
Nicholas Anderson
executiveOkay. Good comment. Just before we answer that question, which I'll defer to Nimesh, because he has been working on those. Just on the Vulcanic, I forgot to mention, but it's very important. Vulcanic has also been working on decarbonization for some years. And another great synergy between us, also because the kind of applications that Vulcanic has been working and been getting orders already like we have for decarbonization are in different applications to the one that Chromalox has been focusing on in the synergy project with Steam. So actually, that's another great synergy opportunity with -- and complementarity with Vulcanic, which is around driving the decarbonization, but not in overlapping up applications, therefore, very, very fully complementary. And of course, their strong presence in Europe. Europe is leading the world in decarbonization. And we expect it will continue to lead the world in that over the coming years, at least the next 5 years, 6 years, for sure. And therefore, in that sense, their strong industrial base in the EMEA region is also strengthening for the decarbonization initiatives. So on that, I'll turn over to Nimesh to answer your question about revenue investments into 2023.
Nimesh Patel
executiveThanks, Jonathan. Yes. So let me just remind everyone what do we mean by revenue investments. So these are costs that go through our P&L, that ultimately help support future years' growth. So we include things like ramping up our manufacturing capacity. The addition of colleagues in our business, who support our supply operations, we include in that, strategic initiatives, so our strategic initiatives around Target Zero that Nick has talked about or indeed rolling out of our digital programs, et cetera. Our commitment to inclusion internally and improving our talent acquisition and retention processes, those sorts of things. And then, of course, we include the expansion of our direct sales force. So our front line that helped drive our growth through our solution-based approach to partnering with our customers and solving their problems. So those things absolutely have been invested in very strongly, right the way back from '21 and continuing into '22. And of course, we were doing that even prior to 2021. So it's been part of our business for a long time. I think the thing that we just need to remind ourselves of, is that in 2021, we were coming out of a challenging period post-COVID. We didn't know how quickly the market was going to recover and what sort of rates of growth we were going to see. And like everyone else, I think we were surprised positively that growth took off as strongly as it did. And you will have seen that in the fact that we upgraded our guidance from what we provided at the beginning of the year in 2021 to where we got to by the end of the year. That meant that some of our revenue investments lagged a little bit, the growth that we saw in the top line, the consequence of which was that they were more weighted to the second half. And therefore, in 2022, we feel the full year impact of those investments. Going forward, we see that starting to line up again. The rate of revenue investments will be much more in line with the growth that we're seeing at the top line, because we're coming out of that recovery period. And the other thing is, some of those manufacturing ramp-ups that we've seen, where we've added a material number of people in our supply organization, particularly in Watson-Marlow, some of those are starting to be behind us. We still got Devens in the second half of this year, but we've delivered a number of these now. We started with Aflex, we've got BioPure, we've got Normandy, and now we've got Devens. So those will be behind us. So my sense is, there'll still be a bit of an impact next year from the full year investments that were -- full year impact of investments that we're making in 2022, but not anywhere in the region of what we've seen this year, as a result of the annualization of last year's investments. Does that answer your question?
Jonathan Hurn
analystNo, that's very clear that you've made that very clear. And maybe I can just sort of squeeze just maybe one quick final one in. Just in terms of Americas team, obviously, growth of 18%. I mean that's a great number. what's essentially driving that? I know, obviously, historically, you've had good growth coming out of places like Argentina and Brazil. I think probably that's -- there's a contribution from that. So if you can just sort of talk around that a little bit? And also just within your Americas team and particularly sort of the U.S.-focused part of that operation? Obviously, a lot of that goes through distributors. What are you seeing in terms of sort of distributor demand? Is there a potential for a bit of a destock or in terms of H2 or things kind of normalized in terms of inventory levels? Just any sort of comments there would be helpful.
Nicholas Anderson
executiveLook, we're very, very pleased with the growth of the steam business in the Americas. And the good thing about it, and we want to call it out is that, it's actually nicely spread across all of the Americas operations. So not only the Latin American operations, which have seen very robust growth even in real terms. So even you say, well, some places like Argentina have been higher replace, and therefore, you've got to get a bit of a higher price. And we've been through those in years past, so Jonathan, you remember that. But we always take those effects out to assess the real terms growth underlining that, and it continues to be robust across all of the America operations, in Latin America and in North America, so USA and Canada. And that is the good -- the nice thing about it is, you can see this consistency come across the U.S., in particular, growing in a nice place as we've been investing for years, to try to accelerate the direct sales element of our sales, retaining our partnerships with distributors, not cannibalizing the relationship with our distributors, but adding more of a direct sales initiatives. And we are seeing slowly, but every year, gradual improvements in that sense, and we've seen that again here. So yes, the U.S. has also seen double-digit growth, and we expect that to continue. And around distribution, having -- adding some destocking or the effects of restock. There's always a little bit of that, as you know. But actually, it's not -- I wouldn't call it out as the main driver of the growth in the USA because we're looking at how much the distribution channel is growing, and we're looking at how much the direct sales channel is growing, and they're both growing and actually direct sales is growing at a faster rate than distribution. So it's pleasing for us to see a normalization at high levels of growth, as we've been investing in for many years.
Operator
operatorAnd the next question comes from the line of Mark Davies Jones from Stifel.
Mark Jones
analystCan I go back to the moving parts of Watson-Marlow? Obviously, even by the very high standards of that business, the last couple of years have been pretty extraordinary. We have seen in some other cases as COVID stuff drops out of the mix. Some of the companies have seen perhaps bigger normalizations than anticipated. So can we get a bit more sense of the moving parts? You still sound very confident on the outlook. But of that 60%, which is pharma and biotech, can you give us any indication of how much of that is currently COVID-related business, do you think?
Nicholas Anderson
executiveAgain, I'd like to remind you, you've heard me say this before, we like to be boringly consistent in what we're saying. So it's always good to remind people of what we've said before. Yes, we have the biopharma sector, and we have the process industry sector, both of which have essentially different drivers. The process industry is driven by IP and above IP also, as we displace other types of pumping technologies -- my question that I mentioned earlier to -- my response to Aurelio's question earlier. So that on the process industry side, not only the correlation to IP, but also the displacement of the types of pumping technologies by our other products accelerates also the growth around the process industry side. And therefore, you can see that coming through strongly in the numbers now in the first half. On the biopharm side, 60% of the business, we've talked since 2020 of -- before 2020, we were talking about the gene therapy, gene and cell therapy treatments that are moving more and more to biotechnology. And that was fueling before COVID something to the tune of, for us, anything between 17% and 20% year-on-year growth of sales into the biopharm sector. And then along came COVID, right and with COVID, we got that additional drive, because all the companies that were developing vaccines for COVID were already well-established customers, and using our products for the development and later for the manufacturers. So COVID brought us that additional demand related to the vaccines. But the underlying demand, the gene and cell therapy drug demand that was already growing at 17% for us, that meant 17%, 20% growth rate, those underlying demand growth rates continued. And so what we're seeing now, is the extra demand of the COVID related part normalizing, as we were expecting. We've been signaling this whole [indiscernible] 2020, early 2021, mid-2021, early 2022, so this is in line with what we were anticipating to say, where you saw that big wave, and therefore, the additional requirements for COVID are less significant. But that underlying demand from the biopharma sector, not related has continued. As the ratio is coming, it's not a little bit higher because I think one of the benefits of COVID is also having demonstrated to the world the virtues of biotechnology and how these technologies can help cure or treat some of the big illnesses like cancer that the world still struggles with. So what we are seeing really is that underlying demand not related to COVID, actually picking up a little bit, at the same time as the other one levels off. So from an order intake point of view, with strong way last year and into the very early parts of this year in terms of stronger order because of the additional COVID-related demand. And that part is kind of tailing off, but the underlying stuff continues to come through. Because those orders were placed and held in the order book, because to be honest, we -- in some of the places where we needed, we didn't even have enough capacity. So some of those orders were being placed for delivery into this year. And that's why you're seeing that demand wave cycling through the sales, and that's why you saw almost close to 30% sales growth in the biopharm sector this year, as we are delivering that higher order book in line with the customer's request. So we see all of the situation normalizing going forward, we see it resuming normal demand patterns and the best test was -- when we look at the [indiscernible] level of order intakes that we're getting, not the year-on-year growth of variances, but the absolute number of pounds coming through, it's still very strong. And hence, we've noted that the order book is still going up, despite the sales rising. So that tells you the demand is there, is still robust and that's what gives us the confidence to be able to say that, we hope to be able to continue growing this business at the rate that we are indicating.
Mark Jones
analystThat's very helpful. And if I can just ask one clarification. You talked about more large projects and CapEx stuff coming back into steam, which I guess we'd expect at this time of the cycle. In the past, you've suggested that, that comes through a rather lower margin. Is it significant enough to have any effect on mix as we look ahead, or is it very much at the edge of the business?
Nicholas Anderson
executiveI think it's the latter part of your question, Mark. This is part of our business and it is part of our business. It's no different with the CapEx side of the business, which, again, reminding people, has historically accounted for about 15% of our total demand, right? Just to put things into perspective, 85% of our business continues to be driven by the customers' OpEx budgets, right? And that other 15%, which is more capacity expansion, CapEx driven, capacity expansion of our customers for customers' CapEx budget. It's a bit more cyclical, as you'd expect, but ultimately, through the cycles, it falls around 15%. Yes, it's a bit lower margin relative to the other 85% OpEx part of our business, but it's not negative margins. It's not poor margin -- occasionally, if somebody makes a mistake, which as humans sometimes happens and we call those out when somebody sells a project that doesn't go well. We have -- but it's marginal thank goodness. So yes, it's in the mix. And when we give you the guidance that we give you for margins going forward, all of this is taken into consideration. So you don't really need to be trying to extrapolate or read in between the lines, we're transparent and straightforward and these effects of the higher CapEx growth is taken into our considerations when we project or we give you guidance on the margins.
Nimesh Patel
executiveAnd we have another question coming in. Okay.
Operator
operatorYes, we're having the last question. And the last question comes from the line of Dominic Convey from Numis.
Dominic Convey
analystJust a couple, if I may, slightly sort of follow-up questions. Just you mentioned, I think, back to the ETS Capital Markets Day that, in reality, the Soissons closure there, would likely not see a benefit until 2023. So I wonder whether you could just remind us what the anticipated net benefit of the action taken there? And if not a specific number then, maybe tie it back into Jonathan's question, I think it was with regard to the investment for growth in 2023 that you said that the drag will be significantly less than what we're seeing this year? And obviously, therefore, can you give us a sense as to whether the expected cost savings at Soissons would be greater or equal to the anticipated drag from investment for growth next year?
Nimesh Patel
executiveOkay. Look, Dominic, thanks for the question, it's Nimesh. Let me just put this in context in terms of our overall journey with respect to ETFs. So we talked previously about 3 things that we are doing, which are incredibly tangible in order to support ETS on its path to improve profitability, on top of making sure we've got the right team, making sure that we're embedding our strategy, making sure that we're embedding our business model in that -- in both Chromalox and Thermocoax. And those 3 things are: one, addressing the losses at Soissons; two, driving higher volumes, and you can see both of those things in our first half results. You can see that we've made the announcement around Soissons, you can see that there's been material volume growth in ETS. And the third was improving pricing, recognizing that we needed to take action there, particularly in EMEA. And that piece will take longer to come through. Again, we've taken the actions, but it takes longer to come through, because we've got a backlog of orders, some of which will be slightly lower margin that we need to work through over time. The net impact of all 3 of those things will be that we will achieve our target, which was guide margins to above 20% 10 years from the point of acquisition -- and ideally, Nick and I would like to get in there and the ETS team more importantly, would like to get there earlier. So that's what we're trying to do. And to give you confidence that it's not an unrealistic target, we remind you that the Chromalox Americas margin is above 20%. So your specific question was around the impact of Soissons. So we're not giving guidance per se on the individual impact of those 3 things and how that will impact margin, other than to say that we expect ETS margin to improve this year and next year. But what I will say is, whereas we won't see the Soissons benefits this year, because we'll carry the cost, but we won't have all the revenues from Soissons. So actually, it's a bit of a headwind in terms of this year's performance. Had we stripped out the impact of Soissons this year, it would be reasonable to expect that the ETS margin overall would have been in the order of 100 basis points better. Okay? So that gives you a little bit of a sense of quantum of the impact from Soissons. Does that help?
Dominic Convey
analystIt does. That's very clear. And just in the context of the ongoing drag from the group-wide investment in growth next year, it feels that, that will still be a net headwind if we were to, actually net off the Soissons benefits?
Nimesh Patel
executiveLook, the way I think about this is there's 2 different things happening. One, we are growing the business, we're making the business more profitable. We're investing some of that back in the form of revenue investments to drive yet more growth and profit improvement, okay? On top of that, we are taking some discrete actions, which underpin greater profitability into the future, which is the 3 things I just talked about. So I wouldn't get too focused on the impact of revenue investments in ETS.
Nicholas Anderson
executiveDominic, it's Nick here. Just as a reminder for you and everybody else, the revenue investments are tailored to the level of organic growth that we can achieve. And you've seen us do this through the years because ultimately, what funds the revenue investment is the operational gearing that we get from the higher sales growth. And as you will recall, when sales growth was higher and [ definitely ] getting more operational gearing, we'd be able to reinvest more into the business. And if you go back to 2019, for example, when it was slowing, we also slowed those revenue investments. But ultimately, what offsets the revenue investments is the operational gearing from the higher sales. And the exception to the rule was this catch-up effect that Nimesh already explained, because at the back end of 2021, we had faster sales growth, it accelerated faster than we could bring those investments in, and that created a lag effect that was normalizing this year, okay? So what was typical was last year's margin, because of that lag effect of the costs. So as you -- but we're confident that, that lag effect is being recovered through this year and therefore, as you start planning and thinking for forward years, you've got to go back to the traditional models, right, which is basically that we will continue to do revenue investments, but those are tailored to the expected level of organic growth and, therefore, funded by the operational gearing, and not going to be a drag on margin progression, as you mentioned going forward, but part of the business as it always has been. Does that help put in a bit more perspective, Dominic?
Operator
operatorDear participants, thank you very much for all your questions. I would now like to hand the conference over to Nicholas for the summary and outlook.
Nicholas Anderson
executiveOkay. Thank you, Nadia. And apologies to everybody I skipped my last slide. When I flip the pages here, my last slide went over with the business one, and so I missed commenting on the last slide, which is Slide 19 in the pack, where we were summarizing and giving the outlook for the year. So although it's a bit late for it, I just wanted to come back and read through Slide 19, which should be up on the screen for you all now. So on Slide 19 with the summary and outlook. The first half revenues are up 17% to GBP 750 million or 15% growth on an organic basis, driven by both volume growth and price increases. The adjusted operating profit in the first half this year is up 10% to GBP 179 million or 9% organically, while the adjusted operating profit margin of 23.8% is down 150 basis points, to the full year effect of the 2021 revenue investments and the 2022 revenue investments. The Vulcanic acquisition strengthens our ETS business and expands our platform for decarbonization solutions. And in terms of outlook, our strong first half performance, together with the record order books and demonstrated resilience through economic cycles, is what underpins our improved outlook for 2022. If the current exchange rates at the end of July were to prevail for the remainder of this year, there would be a tailwind impact on -- close to 3% of sales and 3.5% on operating profit. Overall, we expect group revenues in 2022, excluding contributions from the Vulcanic acquisition, will reflect the typical split of approximately 48% and 52% between the first half and second half of this year, and we expect the full year adjusted operating profit margin in 2022 will be similar to the first half, as we continue those revenue investments for growth, while remaining comfortably above those pre-pandemic levels that we discussed about. So apologies for having skipped that slide earlier on, guys. We're all humans. It's been really great to be receiving your questions. Thanks for signing in and for your support and look forward to catching up with all of you in the near future. Thank you.
Nimesh Patel
executiveThank you.
Operator
operatorThat does conclude our conference for today. Thank you for participating. You may all disconnect. Have a nice day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Spirax Group plc transcript — plus 252,000+ transcripts from 12,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Spirax Group plc earnings transcripts and 252,000+ others is available through the
EarningsCalls.dev REST API. Plans from $24.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.